Home / Intelligence / Webinars / Health Equity in HTA Outcomes: Navigating the New Frontier
Available On Demand
Join Value, Access and Pricing experts Max Hunt, Mary Fletcher-Louis and Pinar Bilir as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
This session will explore how HTA agencies are beginning to include health equity in their access recommendations and discuss the practical impact of this trend. Our experts will share insights from Trinity Life Sciences’ Value Center of Excellence on incorporating the work of health equity teams into access materials in a way that moves the needle for payers.
Key Webinar Topics
- The prevalence of health equity considerations in HTA outcomes
- Practical steps to incorporate health equity into access materials
- The importance of health equity compared to other factors
- Emerging value drivers in the industry
Spotlight Speakers
Max Hunt
Partner,
Evidence, Value, Access & Pricing
Mary Fletcher-Louis
Managing Director &
Head of Value Center of Excellence
Pinar Bilir
Managing Director,
Evidence, Value, Access & Pricing
Complete the form below to view the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Most-Favored Nation Pricing Policy: Why One Size Doesn’t Fit All
September 25, 2025 | 1:00 – 2:00 PM ET
As U.S. leaders promote a drug pricing vision based on Most-Favored Nation (MFN) principles, ensuring that U.S. consumers have access to the best available prices among advanced nations, pharmaceutical companies are facing increased uncertainty and are evaluating strategic options. This session will bring together Trinity experts to discuss how this initiative could realistically lead to […]
Sign Up Now
Blog
A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated loss of insurance coverage for 16 million people[2], fundamentally reshaping access to care for […]
Read More
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
Available On Demand
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Watch Now